Yi N. Xiao
1200 Cailun Road
Shanghai, 201203, China
Shanghai, 201203, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer.
Journal: Cell metabolism
Published: July 30, 2026
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2026
Case of Myelodysplastic Syndrome 15 Years After Kidney Transplantation Under Long-Term Immunosuppression.
Journal: Case reports in hematology
Published: March 09, 2026
Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.
Journal: Cancer biology & medicine
Published: March 06, 2026
CAR-T cell therapy: A new dawn in the treatment of autoimmune disease.
Journal: Cell transplantation
Published: January 20, 2026
Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.
Journal: Case reports in hematology
Published: January 06, 2026
Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer.
Journal: Genome medicine
Published: September 22, 2025
High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.
Journal: Cancer biology & medicine
Published: July 04, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Journal: Molecular cancer
Published: April 28, 2025
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.
Journal: Signal transduction and targeted therapy
Published: April 23, 2025
A Dynamic Contrast-Enhanced MRI-Based Vision Transformer Model for Distinguishing HER2-Zero, -Low, and -Positive Expression in Breast Cancer and Exploring Model Interpretability.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 05, 2025
Last Updated: 09/26/2026